Status:
COMPLETED
An Observational Study to Assess Safety and Effectiveness of Intravenous NovoRapid® in Hospitalised Subjects
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Diabetes Mellitus, Type 1
Eligibility:
All Genders
Brief Summary
This study is conducted in Asia. The aim of this observational study is to evaluate the side effects profile and benefits of using intravenous insulin aspart infusion in hospitalised subjects under no...
Eligibility Criteria
Inclusion
- Any hospitalized subject with hyperglycaemia requiring intravenous insulin therapy is eligible for the study based on the discretion of the physician.
Exclusion
- Subjects who are unlikely to comply with protocol, e.g., uncooperative attitude;
- Subjects with a hypersensitivity to NovoRapid or to any of the excipients.
- Subjects with conditions considered as contraindications.
Key Trial Info
Start Date :
March 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2008
Estimated Enrollment :
3024 Patients enrolled
Trial Details
Trial ID
NCT00700648
Start Date
March 1 2008
End Date
September 1 2008
Last Update
January 4 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Bangalore, India, 560001